Marui Wami, Iseki Eizo, Nakai Toshiki, Miura Satoshi, Kato Masanori, Uéda Kenji, Kosaka Kenji
Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Yokohama 236-0004, Kanazawa, Japan.
J Neurol Sci. 2002 Mar 30;195(2):153-9. doi: 10.1016/s0022-510x(02)00006-0.
Using alpha-synuclein-immunohistochemistry, 27 brains of dementia with Lewy bodies (DLB) were investigated to identify the progression of Lewy pathology including Lewy bodies (LB) and LB-related neurites in the cerebrum. The numbers of alpha-synuclein-positive LB and LB-related neurites were semiquantitatively evaluated in the amygdala, hippocampus, entorhinal cortex, transentorhinal cortex, insular cortex, middle temporal cortex and superior frontal cortex. The results indicated that Lewy pathology within the neuron progresses first in the axonal terminal, subsequently in the cell body and finally in the dendrite, that Lewy pathology in the cerebral cortex progresses first in layers V-VI, subsequently in layer III and finally in layer II, and that Lewy pathology in the cerebrum progresses first in the amygdala, subsequently in the limbic cortex and finally in the neocortex. In addition, Lewy pathology was graded from stage I to stage IV based on the progression of Lewy pathology. The 27 brains examined were classified into 3 brains showing stage I, 11 showing stage II, 7 showing stage III and 6 showing stage IV. Comparing these stages with the pathological subtypes of DLB brains, brains of the subtype showing severe Alzheimer pathology corresponded to brains showing an advanced stage, suggesting that Alzheimer pathology exacerbates Lewy pathology.
利用α-突触核蛋白免疫组织化学方法,对27例路易体痴呆(DLB)患者的大脑进行研究,以确定路易体病理改变的进展情况,包括大脑中路易体(LB)及与LB相关的神经突。对杏仁核、海马体、内嗅皮质、过渡内嗅皮质、岛叶皮质、颞中皮质和额上皮质中α-突触核蛋白阳性的LB及与LB相关的神经突数量进行半定量评估。结果表明,神经元内的路易体病理改变首先在轴突终末出现,随后在细胞体,最后在树突;大脑皮质中的路易体病理改变首先出现在V - VI层,随后在III层,最后在II层;大脑中的路易体病理改变首先在杏仁核出现,随后在边缘皮质,最后在新皮质。此外,根据路易体病理改变的进展情况将其分为I期至IV期。所检查的27例大脑被分为:3例显示I期,11例显示II期,7例显示III期,6例显示IV期。将这些分期与DLB大脑的病理亚型进行比较,显示严重阿尔茨海默病病理改变的亚型大脑对应于晚期大脑,提示阿尔茨海默病病理改变会加剧路易体病理改变。